Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23048458 | 0.80 | KMT2A (0.50) | HDAC6CAPN1POLBMAPT | |
| SCHEMBL30663813 | 0.78 | CAPN1 (0.47) | SMN1; SMN2CAPN1 | |
| SCHEMBL1516186 | 0.74 | RIPK1 (0.71) | HDAC6CA1CA2CA7CA14 | |
| SCHEMBL14253969 | 0.73 | HDAC6 (0.65) | HDAC6CA1CA2CA7CA14 | |
| SCHEMBL18697441 | 0.73 | HDAC6 (0.56) | HDAC6CA1CA2CA7CA14 | |
| Hydrochloric Acid SCHEMBL27727124 | 0.72 | CAPN1 (0.42) | SMN1; SMN2CAPN1 | |
| SCHEMBL1709264 | 0.71 | MEN1 (0.63) | HDAC6CA1CA2CA7CA14 | |
| SCHEMBL1709279 | 0.71 | RAB9A (0.63) | HDAC6CA1CA2CA7CA14 | |
| SCHEMBL29037519 | 0.71 | HDAC6 (0.68) | HDAC6CA1CA2CA7CA14 | |
| SCHEMBL6922051 | 0.71 | CA1 (0.66) | HDAC6CA1CA2CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10173980-B2 | Mixed disulfide conjugates of thienopyridine compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180155289-A1 | MIXED DISULFIDE CONJUGATES OF THIENOPYRIDINE COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10173980-B2 | Mixed disulfide conjugates of thienopyridine compounds and uses thereof | TST, TXN, TXNRD2 | HDAC6 281/4885CA1 3057/4885CA2 2384/4885 |
| US-20180155289-A1 | MIXED DISULFIDE CONJUGATES OF THIENOPYRIDINE COMPOUNDS AND USES THEREOF | TST, TXN, TXNRD2 | HDAC6 281/4885CA1 3057/4885CA2 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.